Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05248009 · ClinicalTrials.gov registry record · NA
Feasibility of Semi-Permanent Tattoo for Treatment Alignment in Radiation Therapy
A NA study of Cancer, Treatment-Related and Tattoo; Pigmentation, sponsored by Henry Ford Health System.
- Completed
- Registry status
- NA
- Development phase
- 15
- Enrollment target
- 1
- Study location
NCT05248009 is a NA study of Cancer, Treatment-Related and Tattoo; Pigmentation that has completed, run by Henry Ford Health System. The registered enrollment target is 15 participants. The trial reports 1 study location across 1 state.
The verdict
NCT05248009, a NA study of Cancer, Treatment-Related and Tattoo; Pigmentation, has completed, sponsored by Henry Ford Health System.
- COMPLETED
- Registry status
- NA
- Development phase
- 15 participants
- Enrollment target
- 1
- Study location
Study Summary
Consenting subjects will receive a semi-permanent tattoo in place of the standard of care permanent tattoo for radiation marking at the time of the radiation planning scan. Subjects will be monitored to ensure alignment is the same with the semi-permanent tattoo as the current standard of care. Subjects will be monitored to ensure there are no skin reactions or other side effects. Subjects will be followed for 15 months and will send pictures to the treatment team to ensure that the tattoo fades away within 12 months as expected.
Conditions Studied
Interventions
- DEVICE Semi-Permanent Tattoo Ink
Study Locations (1)
Michigan
- Henry Ford Health System - Detroit
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2022-06-23 |
| Est. Completion | 2024-09-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05248009
The ClinicalTrials.gov registry entry for NCT05248009 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Henry Ford Health System, which has 234 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Cancer, Treatment-Related appearing as the primary indexed condition, and to 1 intervention - of which Semi-Permanent Tattoo Ink is the first listed.
NCT05248009 reports 1 study location spanning 1 distinct geographic area - top geographies include Michigan.
Frequently Asked Questions
What is clinical trial NCT05248009 about?
NCT05248009 is a clinical study titled "Feasibility of Semi-Permanent Tattoo for Treatment Alignment in Radiation Therapy". Consenting subjects will receive a semi-permanent tattoo in place of the standard of care permanent tattoo for radiation marking at the time of the radiation planning scan. Subjects will be monitored to ensure alignment is the same with the semi-permanent tattoo as the current standard of care. Subj...
What is the current status of trial NCT05248009?
This trial is currently completed. It is a NA study. The enrollment target is 15 participants. The study started on 2022-06-23. Estimated completion is 2024-09-01.
What conditions does trial NCT05248009 study?
This clinical trial studies the following conditions: Cancer, Treatment-Related, Tattoo; Pigmentation.
What interventions are being tested in trial NCT05248009?
The interventions under investigation include: Semi-Permanent Tattoo Ink (DEVICE).
Who is sponsoring clinical trial NCT05248009?
This trial is sponsored by Henry Ford Health System, which has 234 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05248009 being conducted?
This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cancer, Treatment-Related
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.